ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 776

A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission

Katerina Chatzidionysiou1, Carl Turesson2, Annika Teleman3, Ann Knight4, Elisabet Lindqvist5, Per Larsson6, Lars Cöster7, Barbro Rydberg8, Ronald F. van Vollenhoven9 and Mikael Heimbürger10, 1Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, 2Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 3Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, 4Dept of Rheumatology, Institution for Medical Sciences, Uppsala University, Uppsala, Sweden, 5Department of Clinical Sciences, Section for Rheumatology Lund University, Lund, Sweden, 6Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, 7Department of Rheumatology, University Hospital, Linköping, Sweden, 8Department of Rheumatology, Kärnsjukhuset, Skövde, Sweden, 9Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, 10Medical department, Abbott Scandinavia, Stockholm, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adalimumab and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Comparative Efficacy and Novel Treatment Strategies in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Treatment with TNF blockers, once started as therapy for RA, is usually continued indefinitely. Information about the possibility to discontinue anti-TNF therapy in RA patients who have obtained remission is limited. If remission could be sustained after cessation of anti-TNF therapy, this would have vast clinical as well as economic implications. The objective of the ADMIRE trial was to assess the possibility of discontinuing adalimumab treatment while maintaining remission in RA patients in stable remission (DAS 28<2.6 for ≥3 months) on combination therapy with adalimumab + methotrexate (MTX).

Methods:

A randomized, controlled, open label pilot study of RA patients in stable remission treated with adalimumab + MTX. Patients were randomized in a 1:1 ratio to continue with adalimumab + MTX (arm AM) or to discontinue the biologic agent and continue with MTX monotherapy (arm M) for 52 weeks. Flare was defined as DAS28>2.6 or an increase in DAS28 (DeltaDAS28) of more than 1.2 from baseline at any time. Patients in arm M with a flare restarted adalimumab. The primary endpoint was the proportion of patients in remission at week 28 in both arms. Nonresponder imputation (ie, ”flare” imputed) was performed for patients with no available DAS28 at week 28 (this included most patients who had a flare in the M group and restarted adalimumab).

Results:

Thirty-three patients were enrolled in the study and were randomized to arm AM (n=17) and arm M (n=16). One patient in arm AM was excluded (did not fulfill inclusion criteria) and one patient in arm M was excluded due to protocol violation. The median (IQR) age of patients was 61 (53–65) years, median (IQR) disease duration was 8 (5–15) years and 67% were female. Median (IQR)  DAS28 was 1.86 (1.53-2.39) and MTX dose was 20 mg/w (12.5-20) at baseline. At the end of 28 weeks, 15/16 patients (94%) and 5/15 patients (33%) in arms AM and M, respectively, were in remission (P=0.001). In the M group, 3/15 patients were in remission on MTX only. The proportion of patients with a flare during the first 28 weeks in the AM and M arms was 50% (8/16) and 80% (12/15), respectively (P=0.08). The number of patients in the AM and M arms with at least one DeltaDAS28>1.2 during the first 28 weeks was 1/16 (6%) and 8/15 (53%), respectively (P=0.005). Other results from secondary analyses are shown in Table 1.

Table 1. Primary and secondary efficacy endpoints.

Outcome

Arm AM

(adalimumab + MTX)

n=16

Arm M

(MTX)

n=15

Difference between groups*

No. (%) of patients in remission at week 28

15/16 (94%)

5/15 (33%)

0.001

No. (%) of patients with at least 1 flare during first 28 weeks

8/16 (50%)

12/15 (80%)

0.08

No. (%) of patients with at least 1 DAS28>2.6 during first 28 weeks

8/16 (50%)

11/15 (73%)

0.2

No. (%) of patients with at least 1 DeltaDAS28>1.2 during first 28 weeks

1/16 (6%)

8/15 (53%)

0.005

No. (%) of patients with at least 1 DeltaDAS28>0.6 during first 28 weeks

8/16 (50%)

13/15 (87%)

0.04

No. (%) of patients with at least 1 DAS28>2.6 AND DeltaDAS28>1.2 during first 28 weeks

1/16 (6%)

7/15 (47%)

0.01

No. (%) of patients with at least 1 DAS28>2.6 AND DeltaDAS28>0.6 during first 28 weeks

5/16 (31%)

11/15 (73%)

0.02

Relapse-free survival (mean weeks)

22 (95% CI, 18–26)

16 (95% CI, 10–21)

0.05

*Fisher exact test for categorical variables; log-rank (Mantel-Cox) test for survival analysis.

Conclusion:

In this pilot study, remission was rarely maintained in patients with long standing RA who discontinued adalimumab. Compared to patients who continued combination therapy, the proportion in sustained remission was significantly lower for the primary and most secondary endpoints. Adalimumab discontinuation may be feasible in only a minority of patients with established RA in stable clinical remission on adalimumab + MTX.


Disclosure:

K. Chatzidionysiou,
None;

C. Turesson,

Abbott Laboratories,

2,

Pfizer Inc,

2,

Roche Pharmaceuticals,

2,

Abbott Laboratories,

5,

Bristol-Myers Squibb,

5,

Merck Pharmaceuticals,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

UCB pharma,

5;

A. Teleman,
None;

A. Knight,
None;

E. Lindqvist,
None;

P. Larsson,
None;

L. Cöster,
None;

B. Rydberg,
None;

R. F. van Vollenhoven,

Abbott Laboratories,

2,

Bristol-Myers Squibb,

2,

GlaxoSmithKline,

2,

Human Genome Sciences, Inc.,

2,

MSD,

2,

Pfizer Inc,

2,

Roche Pharmaceuticals,

2,

UCB Pharma,

2,

Abbott Laboratories,

5,

Bristol-Myers Squibb,

5,

GlaxoSmithKline,

5,

Human Genome Sciences, Inc.,

5,

MSD,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

UCB Pharma,

5;

M. Heimbürger,

Abbott Laboratories,

3,

Abbott Laboratories,

1.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multicenter-randomized-controlled-open-label-pilot-study-of-the-feasibility-of-discontinuation-of-adalimumab-in-rheumatoid-arthritis-patients-in-stable-clinical-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology